Interventions for fatigue in Parkinson's disease

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 10, 2015, Pages

  Elbers, Roy G ^a,b   Verhoef, John ^a   van Wegen, Erwin E H ^b   Berendse, Henk W ^b   Kwakkel, Gert ^b  

^a UNIVERSITY OF APPLIED SCIENCES LEIDEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CARBIDOPA PLUS LEVODOPA; DOXEPIN; FLUOXETINE; MEMANTINE; METHYLPHENIDATE; MODAFINIL; PAROXETINE; PLACEBO; RASAGILINE; CENTRAL STIMULANT AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

CLINICAL EFFECTIVENESS; COGNITIVE BEHAVIORAL THERAPY; COMPARATIVE EFFECTIVENESS; DAILY LIFE ACTIVITY; DRUG EFFICACY; EPWORTH SLEEPINESS SCALE; FATIGUE; FATIGUE SEVERITY SCALE; FUNCTIONAL STATUS ASSESSMENT; HUMAN; INTERVENTION STUDY; KINESIOTHERAPY; MULTIDIMENSIONAL FATIGUE INVENTORY; NAUSEA; OUTCOME ASSESSMENT; PARKINSON DISEASE; PITTSBURGH SLEEP QUALITY INDEX; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; COMPLICATION; EXERCISE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE AGENTS; EXERCISE; FATIGUE; HUMANS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84973344711     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010925.pub2     Document Type: Review

References (108)

1. Canning C, Allen N, Dean C, Goh L, Fung V. Home-based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clinical Rehabilitation 2012;26:817-26.
2. Lou J, Dimitrova D, Park B, Johnson S, Eaton R, Arnold G, et al. Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study. Clinical Neuropharmacology 2009;32:305-10.
3. Mendonça D, Menezes K, Jog M. Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders 2007;22:2070-6.
4. Ondo W, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind controlled parallel trial. Journal of Neurology Neurosurgery and Psychiatry 2005;76:1636-9.
5. Ondo W, Shinawi L, Davidson A, Lai D. Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders 2011;17:156-9.
6. Postuma R, Lang A, Munhoz R, Charland K, Pelletier A, Moscovich M, et al. Caffeine for treatment of Parkinson disease. Neurology 2012;79:651-9.
7. Rascol O, Fitzer-Attas C, Hauser R, Jankovic J, Lang A, Langston J, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analysis of the need for additional therapies, change in UPDRS scores, and non-motor outcomes. Lancet Neurology 2011;10:415-23.
8. Rios Romenets S, Creti L, Fichten C, Bailes S, Libman E, Pelletier A, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease -a randomized study. Parkinsonism and Related Disorders 2013;19:670-5.
9. Schifitto G, Friedman J, Oakes D, Shulman L, Comella C, Marek K, et al. Fatigue in levodopa-naïve subjects with Parkinson disease. Neurology 2008;71:481-5.
10. Tyne H, Taylor J, Baker G, Steiger M. Modafinil for Parkinson's disease fatigue. Journal of Neurology 2010;257:452-6.
11. Winward C, Sackley C, Meek C, Izadi H, Barker K, Wade D, et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. Movement Disorders 2012;27:143-6.
12. Abe K, Takanashi M, Yanagihara T, Sakoda S. Pergolide mesilate may improve fatigue in patients with Parkinson's disease. Behavioural Neurology 2001;13:117-21.
13. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurology 2010;9:573-80.
14. Barone P. Treatment of depressive symptoms in Parkinson's disease. European Journal of Neurology 2011;18:11-5.
15. Berman R, Thase M, Trivedi M, Hazel J, Vogel Marler S, McQuade R, et al. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatric Disease and Treatment 2011;7:303-12.
16. Blindauer K, Shoulson I, Kieburtz K, McDermott M, Gardiner I, Kamp C, et al. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Archives of Neurology 2003;60:1721-8.
17. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirillineau D, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Movement Disorders 2014;29:1273-80.
18. Bronzova J, Sampaio C, Hauser R, Lang A, Rascol O, Theeuwes A, et al. Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Movement Disorders 2010;25:738-46.
19. Brooks D, Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. Journal of Neurology, Neurosurgery and Psychiatry 2003;74:1071-9.
20. Chaudhuri K, Martínez-Martín P, Antonini A, Brown R, Friedman J, Onofrj M, et al. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism and Related Disorders 2013;19:660-5.
21. Chwieduk C, Curran M. Pramipexole extended release in Parkinson's disease. CNS Drugs 2010;24:327-36.
22. Conradsson D, Lofgren N, Hagstromer M, Stahle A, Franzen E. A highly challenging, progressive and specific balance training program in elderly with Parkinson's disease: theoretical framework and feasibility. European Journal of Neurology 2013;19:S571.
23. Cugusi L, Solla P, Zedda F, Loi M, Serpe R, Cannas A, et al. Effects of an adapted physical activity program on motor and non-motor functions and quality of life in patients with Parkinson's disease. Neurorehabilitation 2014;35:789-94.
24. Dashtipour K, Johnson E, Kani C, Kani K, Hadi E, Ghamsary M, et al. Effect of exercise in motor and nonmotor symptoms of Parkinson's disease. Parkinson's Disease 2015;2015:586378.
25. Datieva V, Rosinskaia A, Levin O. The use of melatonin in the treatment of chronic fatigue sundrome and circadian rhythm disorders in Parkinson's disease. Zhurnal Nevrologii I Psikhiatrii Imeni SS Korsokova 2013;113:77-81.
26. Deuschl G, Vaitkus A, Fox G, Roscher T, Schremmer D, Gordin A. Efficacy and tolerability of entacapone versus cabergoline in Parkinsonian patients suffering from wearing-off. Movement Disorders 2007;22:1550-5.
27. Devos D, Krystkowiak P, Clement F, Dujardin K, Cottencin O, Waucquier N, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 2007;78:470-5.
28. Dobato J, Pérez-Gilabert Y, de Andrés C, Muñoz-Blanco J, Mateo D, Giménez-Roldán S. Effect of amantadine on fatigue in Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis [Efecto del amantadine en la fatiga de la enfermedad de Parkinson, la esclerósis múltiple y la esclerósis lateral amiotrófica]. NeurologÌa 1994;9:460.
29. Dowling G, Mastick J, Colling E, Carter J, Singer C, Aminoff M. Melatonin for sleep disturbances in Parkinson's disease. Sleep Medicine 2005;6:459-66.
30. Drijgers R, Verhey F, Tissingh G, van Domburg P, Aalten P, Leentjens A. The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo controlled experimental challenge with pramipexole and methylphenidate. Journal of the Neurological Sciences 2012;320:121-6.
31. Fernandez H, Greeley D, Zweig R, Wojcieszek J, Mori A, Sussman N. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism and Related Disorders 2010;16:16-20.
32. Genç A, Dönmez Çolakoğlu B, Kara B, Çakmur R. Evaluation of the effects of home-based deep breathing exercises in Parkinson's disease patients. Archives of Neuropsychiatry 2012;49:59-62.
33. Ghahari S, Packer T, Passmore A. Effectiveness of an online fatigue self-management programme for people with chronic neurological conditions: a randomized controlled trial. Clinical Rehabilitation 2010;24:727-44.
34. Grosset K, Grosset D, Lees A. Trial of subtherapeutic pergolide in de novo Parkinson's disease. Movement Disorders 2005;20:363-6.
35. Hauser R, Salin L, Juhel N, Konyago V. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Movement Disorders 2007;22:359-65.
36. Hauser R, Lyons K, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Movement Disorders 2009;24:979-83.
37. Hauser R, Schapira A, Rascol O, Barone P, Mizuno Y, Salin L, et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Movement Disorders 2010;25:2542-9.
38. Heikkinen H, Nutt J, LeWitt P, Koller W, Gordin A. The effects of different repeated doses of entacapone on the pharmacokinetics of l-dopa and on the clinical response to l-dopa in Parkinson's disease. Clinical Neuropharmacology 2001;24:150-7.
39. Jang W, Park J, Shin K, Kim J, Kim J, Youn J, et al. Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson's disease. Journal of the Neurological Sciences 2014;337:47-54.
40. Jankovic J, Watts R, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Archives of Neurology 2007;64:676-82.
41. Kieburtz K, McDermott M, Shoulson I, Fahn S, Brin M, Goetz C, et al. Effect of lazabemide on the progression of disability in early Parkinson's disease. Annals of Neurology 1996;40:99-107.
42. Kieburtz K, The Parkinson Study Group PramiBID Investigators. Twice-daily, low dose Pramipexole in early Parkinson's disease:a randomized, placebo-controlled trial. Movement Disorders 2011;26:37-44.
43. Leentjens A, Scholtissen B, Vreeling F, Verhey F. The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach. Neuropsychopharmacology 2006;31:1009-15.
44. Leroi I, Brandt J, Reich S, Lyketsos C, Grill S, Thompson R, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. International Journal of Geriatric Psychiatry 2004;19:1-8.
45. Lim T, Kluger B, Rodriguez R, Palacio R, Guirati Y, Nutter B, et al. Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease: a 3-center, placebo-controlled, pilot study (the REST trial). Movement Disorders 2013;28:S165.
46. Lou J, Kearns G, Benice T, Oken B, Sexton G, Nutt J. Levodopa improves physical fatigue in Parkinson's diseae: a double-blind, placebo-controlled, crossover study. Movement Disorders 2003;18:1108-14.
47. Meek C, Sackley C, Clarke C, Soundy A, Winward C, Esser P, et al. Long-term individual fitness enablement (LIFE) for Parkinson's disease: a feasibility study. Movement Disorders 2010;25:S713.
48. Menza M, Dobkin R, Marin H, Mark M, Gara M, Buyske S, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886-92.
49. Möller J, Oertel W, Köster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Movement Disorders 2005;20:602-10.
50. Morita A, Okuma Y, Kamei S, Yoshii F, Yamamoto T, Hashimoto S, et al. Pramipexole reduces the prevalence of fatigue in patients with Parkinson's disease. Internal Medicine 2011;50:2163-8.
51. Nutt J, Carter J, Carlson N. Effects of methylphenidate on response to oral levodopa. Archives of Neurology 2007;64:319-23.
52. Okun M, Fernandez H, Rodriguez R, Romrell J, Suelter M, Munson S, et al. Testosterone therapy in men with Parkinson disease. Archives of Neurology 2006;63:729-35.
53. Olanow C, Kieburtz K, Stern M, Watts R, Langston W, Guarnieri M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Archives of Neurology 2004;61:1563-8.
54. Ondo W, Perkins T, Swick T, Hull K, Jimenez J, Garris T, et al. Sodium oxybate for excessive daytime sleepiness in Parkinson disease. Archives of Neurology 2008;65:1337-40.
55. Oved D, Ziv I, Treves T, Paleacu D, Melamed E, Djaldetti R. Effect of dopamine agonist on fatigue and somnolence in Parkinson's disease. Movement Disorders 2006;21:1257-61.
56. Pinter M, Pogarell O, Oertel W. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. Journal of Neurology, Neurosurgery and Psychiatry 1999;66:436-41.
57. Pogarell O, Gasser T, van Hilten J, Spieker S, Pollentier S, Meier D, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. Journal of Neurology, Neurosurgery and Psychiatry 2002;72:713-20.
58. Pourcher E, Fernandez H, Stacy M, Mori A, Ballerini R, Chaikin P. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism and Related Disorders 2012;18:178-84.
59. Richard I, McDermott M, Kurlan R, Lyness J, Como P, Pearson N, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012;78:1229-36.
60. Rios Romenets S, Anang J, Fereshtehnejad S, Pelletier A, Postuma R. Tango for treatment of motor and non-motor manifestations in Parkinson's disease: a randomized control study. Complementary Therapies in Medicine 2015;23:175-84.
61. Sampaio C, Bronzova J, Hauser R, Lang A, Rascol O, Van de Witte S, et al. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. Movement Disorders 2011;26:1464-76.
62. Schapira A, McDermott M, Barone P, Comella C, Albrechts S, Hsu H, et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. The Lancet Neurology 2013;12:747-55.
63. Sethi K, O'Brien C, Hammerstad J, Adler C, Davis T, Taylor R, et al. Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Archives of Neurology 1998;55:1211-6.
64. Shoulson I, Oakes D, Fahn S, Lang A, Langston W, LeWitt P, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of Parkinsonism trial. Annals of Neurology 2002;51:604-12.
65. Singer C, Lamb J, Ellis A, Layton G. A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease. Movement Disorders 2007;22:476-82.
66. Stocchi F. Benefits of treatment with rasagiline in fatigue symptoms in patients with early Parkinson's disease. European Journal of Neurology 2009;16:S525.
67. Stocchi F. Treatment with rasagiline provides benefits in the symptoms of fatigue in patients with early Parkinson's disease. Movement Disorders 2010;25:S676.
68. Stocchi F, Rascol O, Destee A, Hattori N, Hauser R, Lang A, et al. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Movement Disorders 2013;28:1838-46.
69. Stocchi F, The ADAGIO Investigators. Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease. European Journal of Neurology 2014;21:357-60.
70. Sturkenboom I, Graff M, Hendriks J, Veenhuizen Y, Munneke M, Bloem B, et al. Efficacy of occupational therapy for patients with Parkinson's disease: a randomised controlled trial. The Lancet Neurology 2014;13:557-66.
71. Todorova A, Martinez-Martin P, Martin A, Rizos A, Reddy P, Chaudhuri K. Datyime apomorphine infusion combined with transdermal rotigotine patch therapy is tolerated at 2 years: a 24-h treatment option in Parkinson's disease. Basal Ganglia 2013;3:127-30.
72. Trenkwalder C, Zucconi M, Tolosa E, Surmann E, Whitesides J, Boroojerdi B, et al. Effect of rotigotine on sleep outcomes in Parkinson's disease: recover study. Journal of Sleep Research 2010;19:S23-S4.
73. Uc E, Doerschug K, Magnotta V, Dawson J, Thomsen T, Kline J, et al. Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting. Neurology 2014;83:413-25.
74. Watts R, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68:272-7.
75. Zhang L, Zhang Z, Chen Y, Qin X, Zhou H, Zhang C, et al. Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial. International Journal of Neuropsychopharmacology 2013;16:1529-37.
76. Zhang Z, Wang J, Zhang X, Chen S, Wang Z, Zhang B, et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study. Parkinsonism and Related Disorders 2013;19:1022-6.
77. Pahwa R, Tanner C, Hauser R, Sethi K, Isaacson S, Truong D, et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED study). Movement Disorders 2015;30:788-95.
78. Smith K, Eyal E, Weintraub D. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study. JAMA Neurology 2015;72:88-95.
79. Evaluation of the effect of 6 months treatment with DC158AM on fatigue in patients with Parkinson's disease. Multicenter, randomised, double-blind, placebo-controlled study in parallel groups. Ongoing study February 2008 (first enrollment).
80. Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease (REST). Ongoing study December 2009 (first enrollment).
81. Acupuncture for fatigue in Parkinson's disease. Ongoing study August 2010 (first enrollment).
82. Alves G, Wentzel-Larsen T, Larsen J. Is fatigue an independent and persistent symptom in patients with Parkinson's disease?. Neurology 2004;63:1908-11.
83. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th Edition. Arlington: American Psychiatric Association, 2013.
84. Chaudhuri A, Behan P. Fatigue in neurological disorders. Lancet 2004;363:978-88.
85. Cohen J. Statistical Power Analysis in the Behavioral Sciences. 2nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc., 1988.
86. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
87. Elbers R, Rietberg M, Van Wegen E, Verhoef J, Kramer S, Terwee C, et al. Self-report fatigue questionnaires in multiple sclerosis, Parkinson's disease and stroke: a systematic review of measurement properties. Quality of Life Research 2012;21:925-44.
88. Elbers R, Van Wegen E, Verhoef J, Kwakkel G. Reliability and structural validity of the multidimensional fatigue inventory in patients with idiopathic Parkinson's disease. Parkinsonism and Related Disorders 2012;18:532-6.
89. Fox S, Katzenschlager R, Lim S, Ravina B, Seppi K, Coelho M, et al. The Movement Discorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Movement Disorders 2011;26:S2-S41.
90. Franssen M, Winward C, Collet J, Wade D, Dawes H. Interventions for fatigue in Parkinson's disease: a systematic review and meta-analysis. Movement Disorders 2014;29:1675-8.
91. Friedman J, Brown R, Comella C, Garber C, Krupp L, Lou J, et al. Fatigue in Parkinson's disease: a review. Movement Disorders 2007;22:297-308.
92. Friedman J, Alves G, Hagell P, Marinus J, Marsh L, Martínez-Martín P, et al. Fatigue rating scales critique and recommendations by the Movement Disorders Society Task Force on rating scales for Parkinson's disease. Movement Disorders 2010;25:805-22.
93. Friedman J, Abrantes A, Sweet L. Fatigue in Parkinson's disease. Expert Opinion on Pharmacotherapy 2011;12:1999-2007.
94. Frisina P, Tenenbaum H, Borod J. The effects of antidepressants in Parkinson's disease: a meta-analysis. International Journal of Neuroscience 2008;118:667-82.
95. Guyatt G, Oxman A, Vist G, Kunz R, Brozek J, Alonson-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence -study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64:407-15.
96. Havlikova E, Rosenberger J, NagyoveI, Middel B, Dubayova T, Gdovinova Z, et al. Impact of fatigue on quality of life in patients with Parkinson's disease. European Journal of Neurology 2008;15:475-80.
97. Herlofson K, Larsen J. Measuring fatigue in patients with Parkinson's disease -the fatigue severity scale. European Journal of Neurology 2002;9:595-600.
98. Herlofson K, Larsen J. The influence of fatigue on health-related quality of life in patients with Parkinson's disease. Acta Neurologica Scandinavica 2003;107:1-6.
99. Herlofson K, Ongre S, Enger L, Tysnes, O, Larsen, J. Fatigue in early Parkinson's disease. Minor inconvenience or major distress?. European Journal of Neurology 2012;19:963-8.
100. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. BMJ 2003; Vol. 327:557-60.
101. Higgins J, Altman D, Sterne J (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins J, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
102. Johnston B, Thorlund K, Schünemann H, Xie F, Murad M, Montori V, et al. Improving the interpretation of quality of life evidence in meta-analysis: the application of minimal important difference units. Health and Quality of Life Outcomes 2010;8:116.
103. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins J, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
104. Lou J, Kearns G, Oken B, Sexton G, Nutt J. Exacerbated physical fatigue and mental fatigue in Parkinson's disease. Movement Disorders 2001;16:190-6.
105. Martínez-Martín P, Catalan M, Benito-León, Ortega Moreno A, Zamarbide I, Cubo E, et al. Impact of fatigue in Parkinson's disease: the fatigue impact scale for daily use (D-FIS). Quality of Life Research 2006;15:597-606.
106. Schünemann H, Oxman A, Vist G, Higgins J, Deeks J, Glasziou P, Guyatt G. Chapter 12: Interpreting results and drawing conclusions. In: Higgins J, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
107. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox S, Katzenschlager R, et al. The Movement Discorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Movement Disorders 2011;26:S42-S80.
108. Elbers RG, Verhoef J, van Wegen EEH, Berendse HW, Kwakkel G. Interventions for fatigue in Parkinson's disease. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010925]